Industry: Health care Region: France Transaction price: US$ 1 million Transaction method: equity investment
Project introduction:
A French biotechnology company, founded in 2017, focuses on biotechnology of antibody drug research and development. Relying on the self-established antibody discovery and optimization platform, combined with synthetic antibody library and artificial intelligence screening technology, the enterprise can develop fully humanized monoclonal antibodies and antibody derivative therapy for complex targets. Its core research and development pipeline includes new candidate antibodies against major diseases such as cancer. With its technical advantages in antibody engineering, ADC and immune regulation, the company has obtained financial support from the French government's "France 2030" plan and is one of the representative enterprises in the field of antibody drug innovation in France.
Introduction to core technologies:
1. Advanced antibody discovery platform
Combining phage display, yeast display and synthetic antibody library, combined with artificial intelligence screening means, we can quickly identify and optimize fully human antibodies with high affinity and specificity.
2. Ability to deal with complex targets
The company has accumulated rich experience in difficult targets such as transmembrane proteins, ion channels, soluble proteins and peptides, and can develop innovative antibodies that are difficult to cover by traditional technologies.
3. Diversified antibody forms
In addition to standard monoclonal antibodies, enterprises also have the ability to develop cutting-edge therapeutic forms such as pH- sensitive antibodies and antibody drug conjugates (ADC), thus expanding drug application scenarios and therapeutic potential.
Cooperation mode:
To seek partners who need antibody drug research and development technical services in the pharmaceutical field.